+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Chemotherapy Treatment - Global Strategic Business Report

  • PDF Icon

    Report

  • 188 Pages
  • December 2024
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 5997951
The global market for Chemotherapy Treatment was estimated at US$28.2 Billion in 2023 and is projected to reach US$31.5 Billion by 2030, growing at a CAGR of 1.6% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

How Is Chemotherapy Treatment Shaping Cancer Care?

Chemotherapy treatment is a cornerstone of modern cancer care, playing a critical role in the fight against various types of cancer by using powerful drugs to target and destroy rapidly dividing cancer cells. This treatment can be used alone or in combination with other therapies such as surgery, radiation, or immunotherapy to shrink tumors, prevent cancer from spreading, and reduce the risk of recurrence. Chemotherapy has the ability to reach cancer cells throughout the body, making it particularly effective for cancers that have metastasized. Despite its side effects, which can include nausea, fatigue, and hair loss, chemotherapy remains an essential tool in oncology, offering hope to millions of patients by improving survival rates and, in many cases, achieving remission. The evolution of chemotherapy has also led to more personalized approaches, where treatments are tailored to the specific type and stage of cancer, as well as the patient's overall health.

What Innovations Are Enhancing the Effectiveness of Chemotherapy Treatment?

Innovations in chemotherapy treatment are significantly enhancing its effectiveness through the development of targeted therapies, combination treatments, and advanced drug delivery systems. Targeted therapies represent a major advancement, allowing for drugs that specifically attack cancer cells with minimal damage to healthy tissues, thereby reducing side effects and improving patient outcomes. These therapies work by interfering with specific molecules involved in cancer cell growth and survival. Additionally, the use of combination therapies, where chemotherapy is paired with other treatment modalities like immunotherapy or hormonal therapy, has shown to be more effective in some cases by attacking cancer through multiple pathways. Advanced drug delivery systems, such as liposomes, nanoparticles, and antibody-drug conjugates, are also being developed to improve the precision of chemotherapy. These systems help concentrate the chemotherapy drugs in the tumor area, enhancing their efficacy while minimizing systemic exposure and side effects. These innovations are transforming chemotherapy into a more targeted, effective, and patient-friendly treatment option.

How Does Chemotherapy Treatment Impact Patient Quality of Life and Survival Rates?

Chemotherapy treatment has a profound impact on patient quality of life and survival rates, often making the difference between life and death for many cancer patients. While the treatment can be physically and emotionally challenging, its ability to shrink tumors, slow disease progression, and, in some cases, achieve complete remission can extend life expectancy and improve long-term outcomes. Advances in supportive care, such as anti-nausea medications and growth factors, have also improved patients' ability to tolerate chemotherapy, thereby enhancing their quality of life during treatment. Furthermore, the development of less toxic chemotherapy regimens and the use of precision medicine to tailor treatments have reduced the incidence of severe side effects, allowing patients to maintain better overall health and well-being throughout their cancer journey. Despite its challenges, chemotherapy continues to be a lifeline for many, offering the possibility of cure or control of cancer for extended periods.

What Trends Are Driving Growth and Innovation in Chemotherapy Treatment?

Several key trends are driving growth and innovation in chemotherapy treatment, including the rise of personalized medicine, advancements in molecular biology, and the integration of new technologies in drug development. Personalized medicine is increasingly influencing chemotherapy, as genetic profiling of tumors allows for more individualized treatment plans that are tailored to the specific genetic mutations present in a patient's cancer. This approach increases the likelihood of treatment success and reduces unnecessary toxicity. Advances in molecular biology are also leading to the discovery of new drug targets and mechanisms of action, enabling the development of next-generation chemotherapy agents that are more effective and have fewer side effects. The integration of technology, such as artificial intelligence and machine learning, in drug development and patient monitoring is further accelerating innovation in chemotherapy by improving drug discovery, optimizing treatment protocols, and predicting patient responses to therapy. These trends are pushing the boundaries of what is possible in chemotherapy, leading to more effective and personalized cancer treatments that improve patient outcomes and quality of life.

Key Insights:

  • Market Growth: Understand the significant growth trajectory of the Antimetabolites Drug Class segment, which is expected to reach US$10.9 Billion by 2030 with a CAGR of a 2.2%. The Plant Derivatives Drug Class segment is also set to grow at 1.7% CAGR over the analysis period.
  • Regional Analysis: Gain insights into the U.S. market, which was estimated at $7.7 Billion in 2023, and China, forecasted to grow at an impressive 3.6% CAGR to reach $6.0 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

  • Detailed Market Analysis: Access a thorough analysis of the Global Chemotherapy Treatment Market, covering all major geographic regions and market segments.
  • Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
  • Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Chemotherapy Treatment Market.
  • Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

  • How is the Global Chemotherapy Treatment Market expected to evolve by 2030?
  • What are the main drivers and restraints affecting the market?
  • Which market segments will grow the most over the forecast period?
  • How will market shares for different regions and segments change by 2030?
  • Who are the leading players in the market, and what are their prospects?

Report Features:

  • Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2023 to 2030.
  • In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
  • Company Profiles: Coverage of major players such as AbbVie, Inc., Amgen, Inc., AstraZeneca PLC, and more.
  • Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Select Competitors (Total 41 Featured):

  • AbbVie, Inc.
  • Amgen, Inc.
  • AstraZeneca PLC
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Daiichi Sankyo Co., Ltd.
  • F. Hoffmann-La Roche AG
  • Gilead Sciences, Inc.
  • Jazz Pharmaceuticals Plc
  • Kura Oncology
  • Merck & Co., Inc.
  • Novartis International AG
  • Pfizer, Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Takeda Oncology

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Global Economic Update
  • Chemotherapy Treatment - Global Key Competitors Percentage Market Share in 2024 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
  • Advancements in Targeted Chemotherapy and Personalized Treatment Plans
  • Rising Global Cancer Prevalence and the Urgent Need for Effective Treatments
  • Integration of Chemotherapy with Immunotherapy and Other Modalities Enhancing Outcomes
  • Developments in Drug Delivery Systems to Reduce Side Effects and Improve Efficacy
  • Impact of Health Insurance Policies on Chemotherapy Access
  • Data-Driven Oncology: Utilizing Big Data to Inform Treatment Protocols
  • Challenges in Managing Multidrug Resistance in Cancer Therapy
  • Future Trends in Nanoparticles and Its Role in Chemotherapy
4. GLOBAL MARKET PERSPECTIVE
  • Table 1: World Chemotherapy Treatment Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
  • Table 2: World Recent Past, Current & Future Analysis for Chemotherapy Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 3: World Historic Review for Chemotherapy Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 4: World 16-Year Perspective for Chemotherapy Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
  • Table 5: World Recent Past, Current & Future Analysis for Antimetabolites by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 6: World Historic Review for Antimetabolites by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 7: World 16-Year Perspective for Antimetabolites by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • Table 8: World Recent Past, Current & Future Analysis for Plant Derivatives by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 9: World Historic Review for Plant Derivatives by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 10: World 16-Year Perspective for Plant Derivatives by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • Table 11: World Recent Past, Current & Future Analysis for Cytotoxic Antibiotics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 12: World Historic Review for Cytotoxic Antibiotics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 13: World 16-Year Perspective for Cytotoxic Antibiotics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • Table 14: World Recent Past, Current & Future Analysis for Alkylating Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 15: World Historic Review for Alkylating Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 16: World 16-Year Perspective for Alkylating Agents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • Table 17: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 18: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 19: World 16-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
III. MARKET ANALYSIS
UNITED STATES
  • Chemotherapy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
  • Table 20: USA Recent Past, Current & Future Analysis for Chemotherapy Treatment by Drug Class - Antimetabolites, Plant Derivatives, Cytotoxic Antibiotics, Alkylating Agents and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 21: USA Historic Review for Chemotherapy Treatment by Drug Class - Antimetabolites, Plant Derivatives, Cytotoxic Antibiotics, Alkylating Agents and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 22: USA 16-Year Perspective for Chemotherapy Treatment by Drug Class - Percentage Breakdown of Value Sales for Antimetabolites, Plant Derivatives, Cytotoxic Antibiotics, Alkylating Agents and Other Drug Classes for the Years 2014, 2024 & 2030
CANADA
  • Table 23: Canada Recent Past, Current & Future Analysis for Chemotherapy Treatment by Drug Class - Antimetabolites, Plant Derivatives, Cytotoxic Antibiotics, Alkylating Agents and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 24: Canada Historic Review for Chemotherapy Treatment by Drug Class - Antimetabolites, Plant Derivatives, Cytotoxic Antibiotics, Alkylating Agents and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 25: Canada 16-Year Perspective for Chemotherapy Treatment by Drug Class - Percentage Breakdown of Value Sales for Antimetabolites, Plant Derivatives, Cytotoxic Antibiotics, Alkylating Agents and Other Drug Classes for the Years 2014, 2024 & 2030
JAPAN
  • Chemotherapy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
  • Table 26: Japan Recent Past, Current & Future Analysis for Chemotherapy Treatment by Drug Class - Antimetabolites, Plant Derivatives, Cytotoxic Antibiotics, Alkylating Agents and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 27: Japan Historic Review for Chemotherapy Treatment by Drug Class - Antimetabolites, Plant Derivatives, Cytotoxic Antibiotics, Alkylating Agents and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 28: Japan 16-Year Perspective for Chemotherapy Treatment by Drug Class - Percentage Breakdown of Value Sales for Antimetabolites, Plant Derivatives, Cytotoxic Antibiotics, Alkylating Agents and Other Drug Classes for the Years 2014, 2024 & 2030
CHINA
  • Chemotherapy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
  • Table 29: China Recent Past, Current & Future Analysis for Chemotherapy Treatment by Drug Class - Antimetabolites, Plant Derivatives, Cytotoxic Antibiotics, Alkylating Agents and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 30: China Historic Review for Chemotherapy Treatment by Drug Class - Antimetabolites, Plant Derivatives, Cytotoxic Antibiotics, Alkylating Agents and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 31: China 16-Year Perspective for Chemotherapy Treatment by Drug Class - Percentage Breakdown of Value Sales for Antimetabolites, Plant Derivatives, Cytotoxic Antibiotics, Alkylating Agents and Other Drug Classes for the Years 2014, 2024 & 2030
EUROPE
  • Chemotherapy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
  • Table 32: Europe Recent Past, Current & Future Analysis for Chemotherapy Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 33: Europe Historic Review for Chemotherapy Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 34: Europe 16-Year Perspective for Chemotherapy Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
  • Table 35: Europe Recent Past, Current & Future Analysis for Chemotherapy Treatment by Drug Class - Antimetabolites, Plant Derivatives, Cytotoxic Antibiotics, Alkylating Agents and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 36: Europe Historic Review for Chemotherapy Treatment by Drug Class - Antimetabolites, Plant Derivatives, Cytotoxic Antibiotics, Alkylating Agents and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 37: Europe 16-Year Perspective for Chemotherapy Treatment by Drug Class - Percentage Breakdown of Value Sales for Antimetabolites, Plant Derivatives, Cytotoxic Antibiotics, Alkylating Agents and Other Drug Classes for the Years 2014, 2024 & 2030
FRANCE
  • Chemotherapy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
  • Table 38: France Recent Past, Current & Future Analysis for Chemotherapy Treatment by Drug Class - Antimetabolites, Plant Derivatives, Cytotoxic Antibiotics, Alkylating Agents and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 39: France Historic Review for Chemotherapy Treatment by Drug Class - Antimetabolites, Plant Derivatives, Cytotoxic Antibiotics, Alkylating Agents and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 40: France 16-Year Perspective for Chemotherapy Treatment by Drug Class - Percentage Breakdown of Value Sales for Antimetabolites, Plant Derivatives, Cytotoxic Antibiotics, Alkylating Agents and Other Drug Classes for the Years 2014, 2024 & 2030
GERMANY
  • Chemotherapy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
  • Table 41: Germany Recent Past, Current & Future Analysis for Chemotherapy Treatment by Drug Class - Antimetabolites, Plant Derivatives, Cytotoxic Antibiotics, Alkylating Agents and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 42: Germany Historic Review for Chemotherapy Treatment by Drug Class - Antimetabolites, Plant Derivatives, Cytotoxic Antibiotics, Alkylating Agents and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 43: Germany 16-Year Perspective for Chemotherapy Treatment by Drug Class - Percentage Breakdown of Value Sales for Antimetabolites, Plant Derivatives, Cytotoxic Antibiotics, Alkylating Agents and Other Drug Classes for the Years 2014, 2024 & 2030
ITALY
  • Table 44: Italy Recent Past, Current & Future Analysis for Chemotherapy Treatment by Drug Class - Antimetabolites, Plant Derivatives, Cytotoxic Antibiotics, Alkylating Agents and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 45: Italy Historic Review for Chemotherapy Treatment by Drug Class - Antimetabolites, Plant Derivatives, Cytotoxic Antibiotics, Alkylating Agents and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 46: Italy 16-Year Perspective for Chemotherapy Treatment by Drug Class - Percentage Breakdown of Value Sales for Antimetabolites, Plant Derivatives, Cytotoxic Antibiotics, Alkylating Agents and Other Drug Classes for the Years 2014, 2024 & 2030
UNITED KINGDOM
  • Chemotherapy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
  • Table 47: UK Recent Past, Current & Future Analysis for Chemotherapy Treatment by Drug Class - Antimetabolites, Plant Derivatives, Cytotoxic Antibiotics, Alkylating Agents and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 48: UK Historic Review for Chemotherapy Treatment by Drug Class - Antimetabolites, Plant Derivatives, Cytotoxic Antibiotics, Alkylating Agents and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 49: UK 16-Year Perspective for Chemotherapy Treatment by Drug Class - Percentage Breakdown of Value Sales for Antimetabolites, Plant Derivatives, Cytotoxic Antibiotics, Alkylating Agents and Other Drug Classes for the Years 2014, 2024 & 2030
SPAIN
  • Table 50: Spain Recent Past, Current & Future Analysis for Chemotherapy Treatment by Drug Class - Antimetabolites, Plant Derivatives, Cytotoxic Antibiotics, Alkylating Agents and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 51: Spain Historic Review for Chemotherapy Treatment by Drug Class - Antimetabolites, Plant Derivatives, Cytotoxic Antibiotics, Alkylating Agents and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 52: Spain 16-Year Perspective for Chemotherapy Treatment by Drug Class - Percentage Breakdown of Value Sales for Antimetabolites, Plant Derivatives, Cytotoxic Antibiotics, Alkylating Agents and Other Drug Classes for the Years 2014, 2024 & 2030
RUSSIA
  • Table 53: Russia Recent Past, Current & Future Analysis for Chemotherapy Treatment by Drug Class - Antimetabolites, Plant Derivatives, Cytotoxic Antibiotics, Alkylating Agents and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 54: Russia Historic Review for Chemotherapy Treatment by Drug Class - Antimetabolites, Plant Derivatives, Cytotoxic Antibiotics, Alkylating Agents and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 55: Russia 16-Year Perspective for Chemotherapy Treatment by Drug Class - Percentage Breakdown of Value Sales for Antimetabolites, Plant Derivatives, Cytotoxic Antibiotics, Alkylating Agents and Other Drug Classes for the Years 2014, 2024 & 2030
REST OF EUROPE
  • Table 56: Rest of Europe Recent Past, Current & Future Analysis for Chemotherapy Treatment by Drug Class - Antimetabolites, Plant Derivatives, Cytotoxic Antibiotics, Alkylating Agents and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 57: Rest of Europe Historic Review for Chemotherapy Treatment by Drug Class - Antimetabolites, Plant Derivatives, Cytotoxic Antibiotics, Alkylating Agents and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 58: Rest of Europe 16-Year Perspective for Chemotherapy Treatment by Drug Class - Percentage Breakdown of Value Sales for Antimetabolites, Plant Derivatives, Cytotoxic Antibiotics, Alkylating Agents and Other Drug Classes for the Years 2014, 2024 & 2030
ASIA-PACIFIC
  • Chemotherapy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
  • Table 59: Asia-Pacific Recent Past, Current & Future Analysis for Chemotherapy Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 60: Asia-Pacific Historic Review for Chemotherapy Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 61: Asia-Pacific 16-Year Perspective for Chemotherapy Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
  • Table 62: Asia-Pacific Recent Past, Current & Future Analysis for Chemotherapy Treatment by Drug Class - Antimetabolites, Plant Derivatives, Cytotoxic Antibiotics, Alkylating Agents and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 63: Asia-Pacific Historic Review for Chemotherapy Treatment by Drug Class - Antimetabolites, Plant Derivatives, Cytotoxic Antibiotics, Alkylating Agents and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 64: Asia-Pacific 16-Year Perspective for Chemotherapy Treatment by Drug Class - Percentage Breakdown of Value Sales for Antimetabolites, Plant Derivatives, Cytotoxic Antibiotics, Alkylating Agents and Other Drug Classes for the Years 2014, 2024 & 2030
AUSTRALIA
  • Chemotherapy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
INDIA
  • Chemotherapy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
SOUTH KOREAREST OF ASIA-PACIFIC
LATIN AMERICA
  • Chemotherapy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
ARGENTINABRAZILMEXICOREST OF LATIN AMERICA
MIDDLE EAST
  • Chemotherapy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
IRANISRAELSAUDI ARABIAUNITED ARAB EMIRATESREST OF MIDDLE EAST
AFRICA
  • Chemotherapy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
IV. COMPETITION

Companies Mentioned

  • AbbVie, Inc.
  • Amgen, Inc.
  • AstraZeneca PLC
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Daiichi Sankyo Co., Ltd.
  • F. Hoffmann-La Roche AG
  • Gilead Sciences, Inc.
  • Jazz Pharmaceuticals Plc
  • Kura Oncology
  • Merck & Co., Inc.
  • Novartis International AG
  • Pfizer, Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Takeda Oncology

Table Information